IMMUNOPHOTONICS
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a strategic partnership with Veterinary Cancer Therapeutics, LLC. The company was founded in 2008 and is based in Columbia, Missouri.
IMMUNOPHOTONICS
Industry:
Biotechnology Health Care Life Science
Founded:
2008-01-01
Address:
Columbia, Missouri, United States
Country:
United States
Website Url:
http://www.immunophotonics.com
Total Employee:
1+
Status:
Active
Contact:
636-675-6161
Total Funding:
26.9 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Investors List
Zubizoom Investments
Zubizoom Investments investment in Series B - ImmunoPhotonics
iSELECT FUND
iSELECT FUND investment in Series B - ImmunoPhotonics
Immune
Immune investment in Series B - ImmunoPhotonics
ROVAQ Ventures
ROVAQ Ventures investment in Series B - ImmunoPhotonics
National Cancer Institute
National Cancer Institute investment in Grant - ImmunoPhotonics
Tech Coast Angels
Tech Coast Angels investment in Venture Round - ImmunoPhotonics
St. Louis Arch Angels
St. Louis Arch Angels investment in Series A - ImmunoPhotonics
Missouri Technology Corporation
Missouri Technology Corporation investment in Series A - ImmunoPhotonics
iSELECT FUND
iSELECT FUND investment in Series A - ImmunoPhotonics
BioGenerator
BioGenerator investment in Series A - ImmunoPhotonics
Official Site Inspections
http://www.immunophotonics.com Semrush global rank: 5.82 M Semrush visits lastest month: 1.43 K
- Host name: 104.21.76.171
- IP address: 104.21.76.171
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ImmunoPhotonics"
About - Immunophotonics
Immunophotonics is a privately owned clinical-stage biotech company that is pioneering the burgeoning field of Interventional Immuno-Oncology® through the development of novel treatments for solid-tumor cancers. IP-001, the first …See details»
ImmunoPhotonics - Crunchbase Company Profile
ImmunoPhotonics develops immunotherapy-based treatments for cancer. A minimally invasive therapeutic cancer vaccine for the treatment of metastatic …See details»
Tomas Hode, PhD - President, Chief Innovation Officer, Co
Immunophotonics is a privately owned clinical-stage biotech company based in St. Louis, Missouri, with subsidiaries in Bern, Switzerland, and Tianjin, China.See details»
ImmunoPhotonics Company Profile - Office Locations, …
Immunophotonics is a biotechnology company developing a proprietary carbohydrate polymer (N-dihydrogalactochitosan or IP-001). Its technology is intended to be compatible with a variety of …See details»
Immunophotonics, Inc
Immunophotonics is a US-based privately owned clinical stage (Phase 1/2) biotech company developing a first-in-class drug (IP-001) to address the major problem of tumor recurrence …See details»
Immunophotonics, Inc. - Org Chart, Teams, Culture & Jobs - The Org
ImmunoPhotonics has a strategic partnership with Veterinary Cancer Therapeutics, LLC. The company was founded in 2008 and is based in Colu... Read more. Industries. Biotechnology, …See details»
Immunophotonics, Inc. - BIO CEO & Investor Conference | BIO
Feb 7, 2023 1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200 ...See details»
PIONEERING INTERVENTIONAL IMMUNO-ONCOLOGY TM
Immunophotonics.com IRimmunophotonics.com US: 1 (314) 67-019 CH: 41 79 343 493 Industry: Therapeutics, Oncology Stage: Clinical phase 2a, safety & tolerability confirmed in phase 1b …See details»
Immunophotonics, Inc. - Drug pipelines, Patents, Clinical trials
Explore Immunophotonics, Inc. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 2 news, and 10 literature, Disease Domain:Neoplasms ...See details»
Immunophotonics - Interventional Immuno-Oncology®
Apr 16, 2025 Immunophotonics is pioneering the field of Interventional Immunology-Oncologyâ„¢, where a single injection of IP-001 --seamlessly integrated into the clinical workflow--... Read …See details»
Immunophotonics - Arch Grants
Immunophotonics, Inc. is a privately owned clinical-stage biotech company pioneering the field of Interventional Immuno-Oncologyâ„¢. IP-001, the first asset from the company’s intellectual …See details»
Immunophotonics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Immunophotonics, Inc. of Saint Louis, MO. Get the latest business insights from Dun & …See details»
BioGenerator Company Immunophotonics Receives Green Light …
Immunophotonics, Inc. is a privately owned clinical-stage biotech company pioneering the field of Interventional Immuno-Oncologyâ„¢. IP-001, the first asset from the company’s intellectual …See details»
ImmunoPhotonics - Contacts, Employees, Board Members, …
Organization. ImmunoPhotonics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... About. ImmunoPhotonics has 5 current …See details»
FCOI Policy - Immunophotonics
N I H F C O I P O L I C Y. COMPANY-WIDE POLICY: GRANT FUNDING FINANCIAL CONFLICT OF INTEREST DISCLOSURES. SCOPE: Company Wide. Immunophotonics, Inc. …See details»
Pipeline - Immunophotonics
IP-001 A novel cationic immune stimulant The first asset from Immunophotonics’ broad intellectual property portfolio. IP-001 Oncology Transforming tumor ablations into a systemic …See details»
Immunophotonics Receives Green Light from FDA to Open …
May 16, 2023 Immunophotonics, Inc. is a privately owned clinical-stage biotech company pioneering the field of Interventional Immuno-Oncologyâ„¢. IP-001, the first asset from the …See details»
Careers - Immunophotonics
We’re passionate about developing the novel field of IIO. We are seeking cross-functional expertise in everything from ablation to immunotherapy with a focus on those with a strong …See details»
Patients - Immunophotonics
Immunophotonics’s investigational treatment involves injecting a proprietary drug, IP-001, directly into the ablated tumor(s) immediately after the ablation. This drug is designed to capture the …See details»
Technology - Immunophotonics
Like all T cells, these are white blood cells that originate from the bone marrow and develop in the thymus. CD8+ T cells, also known as cytotoxic T lymphocytes (CTLs), are the primary …See details»